Slideshow

Hydroxychloroquine in Lupus: Strategies to Minimize Ocular Toxicity

The challenge: how to maintain therapeutic drug levels in the face of ocular toxicity.

References1. Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol. 2018;30:249-255. doi: 10.1097/BOR.0000000000000500.2. Marmor MF, Kellner U, Lai TY, et al; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415-422.3. Marmor MF, Kellner U, Lai TY, et al; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386-1394.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Related Content
CASPAR Criteria May Identify More Patients With Juvenile PsA Than ILAR Criteria
December 21st 2024

CASPAR Criteria May Identify More Patients With Juvenile PsA Than ILAR Criteria

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Credit: US Food and Drug Administration
December 17th 2024

FDA Accepts New Drug Application for TNX-102 SL in Fibromyalgia

Chelsie Derman
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Natalie V. Scime, PhD, who was a Banting Postdoctoral Fellow at Institute for Clinical Evaluative Sciences (ICES) and the Department of Health and Society at the University of Toronto Scarborough
December 5th 2024

Women Who Give Birth After Infertility Have Elevated Risk of Systemic Rheumatic Disease

Victoria Johnson
Yazmin Rustomji, MD, a resident at Rush University Medical Center
December 4th 2024

Patient Education Materials for Rheumatology, Internal Medicine Don’t Meet Readability Standards

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.